(Q37652173)

21 August 2017

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer (English)

1 reference

21 August 2017

0 references

1 reference

7

Alexia Iasonos

1 reference

21 August 2017

1

Rachel N Grisham

1 reference

21 August 2017

12

Carol Aghajanian

1 reference

21 August 2017

Gopa Iyer

2

1 reference

21 August 2017

Karuna Garg

3

1 reference

21 August 2017

Deborah Delair

4

1 reference

21 August 2017

David M Hyman

5

1 reference

21 August 2017

Qin Zhou

6

1 reference

21 August 2017

Michael F Berger

8

1 reference

21 August 2017

Fanny Dao

9

1 reference

21 August 2017

David R Spriggs

10

1 reference

21 August 2017

Douglas A Levine

11

1 reference

21 August 2017

David B Solit

13

1 reference

21 August 2017

language of work or name

English

0 references

publication date

28 August 2012

1 reference

21 August 2017

1 reference

21 August 2017

119

1 reference

21 August 2017

3

1 reference

21 August 2017

548-554

1 reference

Low-grade serous carcinomas of the ovary contain very few point mutations

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Integrated genomic analyses of ovarian carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3961140

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors

1 September 2018

1 reference

12 December 2020

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

1 reference

12 December 2020

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

1 reference

12 December 2020

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

1 reference

12 December 2020

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.27782

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

22930283

1 reference